This randomized controlled trial investigated the impact of testosterone replacement therapy (TRT) on prostate safety in men with hypogonadism. A total of 5,204 men aged 45-80 years were treated with topical 1.62% testosterone gel for an average of 21.8 months. The study found no significant difference in the incidence of
